Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of ...

MyHealthTeam, a Swoop company, the creator of one of the largest, engaged patient social networks in healthcare, has ...

AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment -- ...